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diSconTinuation in CrOhn’s d
combined therapy with ImmunoTools for stratification of relapse risk of Crohn’s disease (CD) after anti–tumor necrosis factor
(TNF) therapy cessation are needed. We aimed to validate a previously developed prediction
model from the diSconTinuation in CrOhn’s disease patients in stable Remission on combined
therapy with Immunosuppressants (STORI) trial, and to develop an updated model.METHODS: Cohort studieswere selected that reported on anti-TNF cessation in 30 ormore CDpatients in remission.
Individual participant datawere requested for luminal CD patients and anti-TNF treatment duration of 6
months or longer. The discriminative ability (concordance-statistic [C-statistic]) and calibration
(agreement between observed and predicted risks) were explored for the STORI model. Next, an
updated prognostic model was constructed, with performance assessment by cross-validation.RESULTS: This individual participant data meta-analysis included 1317 patients from 14 studies in 11
countries. Relapses after anti-TNF cessation occurred in 632 of 1317 patients after a median of
13 months. The pooled 1-year relapse rate was 38%. The STORI prediction model showed poor
discriminative ability (C-statistic, 0.51). The updated model reached a moderate discriminative
ability (C-statistic, 0.59), and included clinical symptoms at cessation (hazard ratio [HR], 2.2;
95% CI, 1.2–4), younger age at diagnosis (HR, 1.5 for A1 (age at diagnosis £16 years) vs A2 (ageer: C-statistic, concordance-statistic; CD,
tive protein; FC, fecal calprotectin; HR,
ual participant data meta-analysis; IS,
hysicians’ Global Assessment; STORI,
isease patients in stable Remission on
suppressants; TNF, tumor necrosis factor.
© 2021 by the AGA Institute. Published by Elsevier Inc. This is an open




2 Pauwels et al Clinical Gastroenterology and Hepatology Vol. -, No. -at diagnosis 17 - 40 years); 95% CI, 1.11–1.89), no concomitant immunosuppressants (HR, 1.4;
95% CI, 1.18–172), smoking (HR, 1.4; 95% CI, 1.15–1.67), second line anti-TNF (HR, 1.3; 95% CI,
1.01–1.69), upper gastrointestinal tract involvement (HR, 1.3 for L4 vs non-L4; 95% CI, 0.96–
1.79), adalimumab (HR, 1.22 vs infliximab; 95% CI, 0.99–1.50), age at cessation (HR, 1.2 per 10
years younger; 95% CI, 1–1.33), C-reactive protein (HR, 1.04 per doubling; 95% CI, 1.00–1.08),
and longer disease duration (HR, 1.07 per 5 years; 95% CI, 0.98–1.17). In subanalysis, the
discriminative ability of the model improved by adding fecal calprotectin (C-statistic, 0.63).CONCLUSIONS: This updated prediction model showed a reasonable discriminative ability, exceeding the
performance of a previously published model. It might be useful to guide clinical decisions on
anti-TNF therapy cessation in CD patients after further validation.Keywords: Crohn’s Disease; Anti-TNF Cessation; Prediction.Anti-tumor necrosis factor (TNF) therapy is apivotal therapy for the induction and mainte-
nance treatment of patients with moderate to severe
Crohn’s disease (CD).1,2 After its launch, the biological
exposure rate in CD patients has increased markedly
from 3% to 41% over the past 2 decades.3 Despite the
expanding arsenal of medication options in CD, the use of
anti-TNF therapy may increase further with the introduc-
tion of biosimilars and with changing treatment para-
digms including top-down and treat-to-target
strategies.4,5 Notwithstanding its beneficial effect, impor-
tant drawbacks of prolonged anti-TNF therapy are side
effects and possibly an increased risk of malignancy. Ma-
lignancies associated with the use of anti-TNF therapy
include nonmelanoma skin cancer, melanoma, and solid
organ and lymphoproliferative malignancies.6 However,
a causal relationship is difficult to ascribe to the use of
anti-TNF therapy, especially because of the sequential
or concomitant use of thiopurines. Recently, chronic fa-
tigue and work productivity loss have been associated
with long-term anti-TNF therapy.7 Finally, the direct
health care costs of anti-TNF therapy remain high, even
in the era of biosimilars.8,9 Anti-TNF therapy cessation
is a difficult decision in clinical practice because predic-
tors of the risk of relapse after cessation can be insuffi-
ciently weighed on an individual patient level.10 The
overall risk of CD relapse within 1 year after anti-TNF
therapy cessation is considerable, and estimated at
approximately 40% in CD patients in clinical remission.11
Although several publications have investigated risk fac-
tors of relapse after anti-TNF therapy cessation, most
publications lack sufficient power for adequate risk
assessment. In the diSconTinuation in CrOhn’s disease
patients in stable Remission on combined therapy with
Immunosuppressants (STORI) trial, risk factors of
relapse after step-down from the combination of immu-
nosuppressant (IS) and anti-TNF therapy to IS monother-
apy were identified.12 However, the STORI prediction
model for anti-TNF cessation has not yet been adopted
in guidelines or implemented in routine clinical care.
In this study, we aimed to validate the STORI pre-
diction model and to update the model by pooling datafrom current literature in an individual participant data
meta-analysis (IPD-MA). Second, we aimed to develop a
patient stratification tool to allow for identification of CD
patients in remission at low or high risk of relapse after
anti-TNF therapy cessation.
Methods
An IPD-MA of published studies was conducted
following the guidelines of Preferred Reporting Items for
Systematic Reviews and Meta-analysis.13 In addition, the
Meta-analysis Of Observational Studies in Epidemiology
checklist was used, containing specifications for the
reporting of a meta-analysis of observational studies14 and
reporting followed the Transparent Reporting of a multi-
variable prediction model for Individual Prognosis Or
Diagnosis guidelines.15 The study protocol was approved by
the Medical Ethical Review Committee of the Erasmus
University Medical Center (MEC-2019-0359) and was
registered in the International prospective register of sys-
tematic reviews (PROSPERO) register (CRD42019131607).
Search Strategy
A comprehensive systematic search was designed in
collaboration with the Medical School Library of Erasmus
University (Rotterdam, The Netherlands) and was con-
ducted on February 26, 2020, in Embase, Medline, Web
of Science, the Cochrane database, and Google scholar.
Studies evaluating the incidence and risk factors of
relapse after anti-TNF therapy cessation in CD patients in
remission were selected. The search was conducted us-
ing controlled vocabulary supplemented with keywords
(Supplementary Figure 1). In addition, abstracts were
included. Abstracts published on international con-
gresses additionally were found by a manual search in
the abstract books of American Digestive Disease Week,
United European Gastroenterology Week, and the Con-
gresses of the European Crohn’s and Colitis Organisation.
In case of incomplete data in abstracts, authors were
contacted to obtain complete data. The retrieved studies
What You Need to Know
Background
In this meta-analysis based on individual patient
data of previous study cohorts, a prediction model
was developed to prognosticate relapse risk after
anti–tumor necrosis factor (TNF) therapy cessation
in Crohn’s disease (CD) patients in remission. Anti-
TNF therapy cessation in CD patients in remission
is a difficult decision in clinical practice because
predictors of the risk of relapse after cessation can
be insufficiently weighed on an individual patient
level.
Findings
With meta-analysis data from 1317 individual pa-
tients from 14 studies, an updated prediction model
with routinely available parameters was
constructed.
Implications for patient care
The provided clinical score chart based on the
updated prediction model might guide clinical de-
cisions on anti-TNF cessation in CD patients.
- 2021 Predicting Safe Anti-TNF Cessation 3were screened and selected based on the inclusion and
exclusion criteria by 2 independent reviewers (R.W.M.P.
and J.A.M.S. [CEASE Study Group]). Discrepancies were
solved after consensus with a third party (A.C.d.V.).
Study and Patient Selection
Cohort studies evaluating the incidence and risk factors
of relapse after anti-TNF therapy (infliximab or adalimu-
mab) cessation in CD patients in remission were included
according to the following criteria: (1) size of the study
population of greater than 30 patients (2) duration of anti-
TNF therapy of 6 months or longer; (3) concomitant
therapy with IS was allowed; (4) luminal CD as indication
for anti-TNF therapy; and (5) full-text or abstract avail-
ability in English language. The following studies were
excluded: perianal disease as an indication for anti-TNF
therapy and (systematic) reviews and editorial letters.
After obtaining the IPD from the study cohorts, patients
were included only when in documented remission at
baseline, defined as steroid-free clinical, biochemical, or
endoscopic disease remission, that is, Crohn’s Disease Ac-
tivity Index less than 150/Harvey Bradshaw Index less
than 5/Physicians’ Global Assessment (PGA) score of
0 (the PGA consists of a 4-point scale, divided as follows:
remission, 0; mild, 1; moderate, 2; and severe disease, 3);
or fecal calprotectin (FC) level of less than 150 mg/g or C-
reactive protein (CRP) level of less than 10 mg/L; or
endoscopic remission defined as a simple endoscopic score
for CD of 0 to 2, Crohn’s disease index of severity less than
3, Rutgeerts score of 0 to 1, or no ulcerations/mucosal
healing. Patients were excluded as follows: (1) age youngerthan 16 years, (2) duration of anti-TNF therapy shorter
than 6 months, and (3) perianal disease activity as indi-
cation for anti-TNF therapy.
Outcome Parameters
The primary outcome was a relapse of CD that
necessitated (re)introduction of biologicals, glucocorti-
costeroids, IS, or surgery for CD luminal activity or
complications.
Request of Individual Participant Data
For each selected study, the corresponding authors
were contacted to request the IPD. Terms and conditions
for transfer and use of the data were specified in a data
transfer agreement, signed by both the data provider and
receiver. The IPD were de-identified.
Individual Participant Data Integrity
All included IPD were checked on missing-, invalid-,
or out-of-range data, and (in)-consistency. All biochem-
ical markers were transformed to standardized and
consistent units. Any inconsistency was queried and
solved with the corresponding authors. Data manage-
ment was executed following recently published guide-
lines supported by the Amsterdam University Medical
Centre directive for data management and incorporation
of new European legislation on privacy protection.16
Risk of Bias and Quality-of-Evidence
Assessment
Risk of bias and quality of evidence were assessed by
2 investigators (R.W.M.P. and J.A.M.S. [CEASE Study
Group]) using the Newcastle–Ottawa Quality Assessment
Form for Cohort Studies and the prediction model risk of
bias assessment tool.17,18
Statistical Analyses
Descriptive statistics were used for baseline charac-
teristics. Continuous data were presented as median and
first and third quartiles. Categoric data were presented
in percentages. The chi-square test, Wilcoxon rank-sum
test, or t tests were used to evaluate differences be-
tween patients in categoric or continuous (not) normally
distributed data. A 2-sided P value of less than .05 was
considered significant.
Kaplan–Meier survival analysis was used to assess
the risk of relapse after anti-TNF cessation.
Kaplan–Meier curves were constructed for each included
study. Pooled relapse rates at 1 and 2 years were esti-
mated in a random-effects meta-analysis. A multivariable
Cox proportional hazard regression model with stratified
4 Pauwels et al Clinical Gastroenterology and Hepatology Vol. -, No. -baseline hazards for study was used to evaluate factors
related to time to relapse after anti-TNF cessation.
First, we validated the STORI model on all patients
from studies measuring FC. For the second cohort, in-
clusion criteria of the STORI trial were used to select a
subpopulation (ie, steroid-free clinical remission, age
17 y, 1 year infliximab therapy, and baseline IS use).
Discrimination was quantified by a Harrell’s concordance
statistic (C-statistic).19,20 Calibration was evaluated
graphically using a calibration plot and quantified
through calibration-in-the-large and the calibration
slope. Second, updated IPD-MA prediction models were
constructed considering potential risk factors for relapse.
The risk factors for relapse were selected based on the
literature.10,11 These factors comprised the following: (1)
demographics and disease characteristics: age, sex,
smoking, disease duration, Montreal classification, his-
tory of intestinal resection, and clinical remission (based
on the Crohn’s Disease Activity Index, Harvey Bradshaw
Index, and/or PGA score); (2) medication use: previous
anti-TNF exposure, type of anti-TNF (infliximab or ada-
limumab), intensified anti-TNF dose or interval, duration
of anti-TNF therapy, previous IS use, numbers of previ-
ous IS, concomitant use of IS, type of IS, and corticoste-
roid use before cessation of anti-TNF; (3) biochemical
markers: hemoglobin level (mmol/L), leukocyte count
(109/L), thrombocytes (109/L), serum albumin (g/L),
CRP (mg/L), FC level (mg/g), anti-TNF serum concen-
tration (mg/mL), and antidrug antibody concentrations
(ng/mL); and (4) endoscopy and imaging: endoscopic
remission (simple endoscopic score for CD/Crohn’s dis-
ease index of severity), and radiologic remission (mag-
netic resonance imaging of the bowel; preferably by
validated scores, otherwise by assessment by a local
radiologist). The prediction models were developed ac-
cording to modern statistical methods.15,21–23 Three
prediction models for relapse were constructed in a step-
wise approach: (1) clinical model, including variables on
demographics and disease characteristics; (2) biochem-
ical model, including the predictors from the clinical
model plus biochemical markers; and (3) endoscopic
model, including clinical and biochemical predictors plus
variables on endoscopy and imaging. For the assessment
of the association of FC and relapse risk, separate models
with the inclusion of the identified clinical, biochemical,
and endoscopic risk factors were constructed based on
the subpopulation from 8 of 14 studies (297 patients)
that recorded FC.3,7–10,12–14 For this analysis, FC was log-
transformed. The selection criterion to incorporate a risk
factor into the prediction model was a P value less than
0.2.26 Possible nonlinear associations between contin-
uous predictors and the probability of relapse were
assessed using restricted cubic splines. If there was ev-
idence of a nonlinear association the restricted cubic
spline was approximated using a simpler function (eg,
logarithmic/quadratic function). Missing data were
imputed using the mice algorithm in R when the per-
centage of missing values was less than 50 for clinicalparameters and less than 60 for continuous biochemical
data.24,27 Clustering at the study level was considered
when missing data were imputed.
In addition, we included the cumulative hazard of the
time until relapse and the relapse indicator in the
imputation model. Missing values were imputed 5 times
and statistical analyses were performed on each of the
imputed data sets and results were pooled using Rubin
rules. Validation of the developed model was performed
using an internal–external validation procedure, which
means that every study was left out once to validate the
models developed in the remaining studies. The
discriminative ability of each prediction model was
assessed using the C-statistic.19,20 A pooled C-statistic
was estimated with a random-effects model to indicate
the overall performance. The calibration of the prediction
model was quantified using the calibration-in-the-large
and the calibration slope. Heterogeneity in performance
across studies was quantified by the I2 statistic.28 The
95% CIs and prediction intervals of the pooled perfor-
mance measures were calculated.29 Clinical usefulness of
the developed model was assessed using decision curve
analysis.30 We assessed the ability of the prediction
model to make a better selection of patients to stop anti-
TNF treatment compared with the default strategies of
continuing anti-TNF treatment in all patients or stopping
anti-TNF treatment in all patients. In decision curve
analysis, the net benefit of using a prediction model is
calculated by summing the benefits (correctly identifying
patients who would relapse within 1 year) and sub-
tracting the harms (continuing anti-TNF treatment
within patients who would not relapse within 1 year)
using a weighting factor. This weighting factor is related
to the number of patients the physician is willing to
continue on anti-TNF treatment who will not relapse in 1
year to correctly identify 1 patient who will relapse
within 1 year. The risk threshold (and corresponding
weighting factor) is subjective to the preferences of pa-
tients and the physician, therefore we investigated the
clinical usefulness across a range of thresholds. A score
chart was constructed for the final presentation of the
updated prediction model.Results
Identification of Studies
From a total of 6561 studies identified after the
electronic database search, 4364 studies were excluded
after screening of titles and abstracts (Supplementary
Figure 2). After full-text reading, 29 studies fulfilled the
eligibility criteria. After contacting the corresponding
authors, the IPD were obtained for 1777 patients from
14 studies (Supplementary Figure 3). The included
studies comprised 8 retrospective and 6 prospective
cohort studies, 12 studies from Europe, 1 study from
Asia, and 1 study from North America (Table 1,
Table 1. Characteristics of the 14 Included Studies




participants, N Relapse, N Definition of remission Definition of relapse
Lu et al31 Retrospective Canada 2010 34 21 Steroid free clinical
remission with CDAI
<150
Physician or hospital visit for
documented symptoms of disease
activity and a therapeutic intervention
with CD medication(s), or a
hospitalization with complications
related to active CD
Louis et al12 Prospective France and
Belgium
2012 115 52 Steroid-free clinical
remission; CDAI <150
CDAI >250 or CDAI between 150 and
250 with >70 point increase from
baseline over 2 weeks
Molnár et al32 Prospective Hungary 2012 103 47 Clinical remission; CDAI
150
CDAI rise of >100 points and CDAI of
>150 points




Re-treatment with a biologic, systemic
steroid or surgery Introduction or
dose increase in an
immunosuppressant
Chauvin et al34 Retrospective France 2014 34 23 Clinical remission; HBI<4 HBI >4 or the need to introduce any
specific treatment for CD
Farkas et al35 Prospective,
multicenter
Hungary 2014 19 10 Clinical remission; CDAI
<150
An increase of >100 points in CDAI and
a CDAI of >150
Ben-Horin et al36 Retrospective,
multicenter
France 2015 29 15 Clinical remission; HBI 4
or CDAI 150
Re-emergence of symptoms
accompanied by objective evidence
of IBD inflammation (increased CRP
or FC, evidence of active
inflammation on endoscopy or
imaging, or appearance of a draining
fistula)
Bortlik et al37 Prospective Czech Republic 2015 48 27 Steroid free clinical and
endoscopic (no
ulcerations) remission
Defined as a clinical exacerbation of the
disease confirmed by endoscopy
and/or another imaging procedure)
with or without laboratory (CRP or
FC) or new onset of perianal disease
(abscess or fistula) leading to a
change in medical therapy or to
surgery
Brooks et al38 Prospective,
multicenter
United Kingdom 2015 62 28 Clinical remission; PGA:
remission
Recurrent symptoms of Crohn’s disease



















participants, N Relapse, N Definition of remission Definition of relapse
Kennedy et al39 Retrospective,
multicenter
United Kingdom 2016 143 73 Steroid-free clinical
remission
The requirement of a therapeutic
intervention (steroids,
immunosuppressants, anti-TNF,
hospital admission, or surgical
resection)
Casanova et al40 Retrospective,
multicenter
Spain 2017 562 249 Clinical remission; HBI 4
points
The onset of documented clinical,
biochemical, endoscopic, or
radiologic activity leading to a
therapeutic intervention
García-Ortíz et al25 Abstract,
retrospective
Spain 2017 56 25 Endoscopic remission;
mucosal healing
NR
Lin et al41 Retrospective,
multicenter
Taiwan 2017 36 21 Clinical remission; CDAI
<150
CDAI score of 70 points, or a CDAI
score of >250
Bots et al42 Prospective The Netherlands 2019 66 36 Clinical remission; PGA:
remission and/or
biochemical (FC <250
mg/g and CRP<5 mg/L)
and/or endoscopic/
radiologic (no signs of
inflammation)
The requirement for (re)treatment with
IBD medication (ie, corticosteroids,
immunosuppressants, biologicals, or
experimental medication), dose





median (Q1–Q3), mo IFX/ADA, N (%)
Number of






Lu et al31 13 (11–24) IFX, 34 (100) Median, 8 (2–51) Azathioprine, 14 (64)
6-Mercaptopurine, 1 (5)
Methotrexate, 5 (23)
Both azathioprine and methotrexate, 2 (9)
(12 missing values)
NR Yes
Louis et al12 26 (18–37) IFX, 115 (100) At least 2
2 infusions 14 (12)
3 infusions 74 (64)




























































Farkas et al35 12 (NR) IFX, 14 (74)
ADA, 5 (26)
NR Azathioprine, 7 (100)
(12 missing values)
NR NR
Ben-Horin et al36 24 (14–30) IFX, 23 (79)
ADA, 6 (21)





Bortlik et al37 23 (NR) IFX, 33 (69)
ADA, 15 (31)
NR NR; 77% on immunosuppressan NR Yes
Brooks et al38 22 (14–28) IFX, 54 (87)
ADA, 8 (13)





Kennedy et al39 29 (17–46) IFX, 117 (80)
ADA, 29 (20)





Casanova et al40 23 (14–40) IFX, 358 (64)
ADA, 204 (36)





García-Ortíz et al25 25 (14–40) IFX, 34 (52)
ADA, 31 (48)
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studies scored between 5 and 8 stars (maximum, 9) ac-
cording to the Newcastle–Ottawa Quality Assessment
Form for Cohort Studies, and an overall unclear risk of
bias according to the prediction model risk of bias
assessment tool, which indicates a low-to-medium risk of
bias for prognostic relations (Supplementary Tables 3
and 4).
Patient Characteristics
In accordance with the predefined inclusion and
exclusion criteria, 1317 patients were included in the IPD-
MA (567 [43%] males; median age, 35 years [28–45 y])
(Table 2). Anti-TNF therapy was infliximab in 927 patients
(70%) and adalimumab in 390 patients (30%), and was
discontinued after a median disease duration of 7.7 years
(3.7–13.0 y) and a median anti-TNF treatment duration of
23 months (14–40 mo). In total, 933 (71%) patients used
concomitant IS therapy at anti-TNF cessation. In 632 of
1317 patients a relapse occurred after a median follow-up
period of 13 months (7–28 mo). The overall cumulative 1-
and 2-year relapse rates were 38% (33%–42%) and 52%
(46%–57%) (Supplementary Figure 4). The heterogeneity
in observed relapse rates was moderate between studies
(I2 ¼ 57% and 54%, respectively).
DiSconTinuation in CrOhn’s Disease Patients in
Stable Remission on Combined Therapy With
Immunosuppressants Trial Model Validation
Validation of the STORI prediction model in the 14
cohorts showed a poor discriminative ability (cross-
validated C-statistic, 0.51; 95% CI, 0.47–0.56)
(Figure 1A). A second validation cohort included a sub-
population of the total study cohort, which consisted of
143 patients fulfilling the inclusion criteria of the STORI
trial. Similar to the first cohort, the discriminative ability
of the STORI prediction model was poor (C-statistic,
0.51; 95% CI, 0.17–0.84) (Figure 1B and C).
Clinical Model
In the clinical model, the combination of 9 predictors
resulted in a somewhat better discriminative ability (C-
statistic, 0.59; 95% CI, 0.56–0.61) (Table 3,
Supplementary Table 5). Clinical remission was an
important protective factor (hazard ratio [HR], 0.45; 95%
CI, 0.24–0.84), as well as continuation of IS at the
moment of anti-TNF cessation (HR, 0.70; 95% CI,
0.58–0.85). The type of anti-TNF used at the time of
cessation and previous use were associated with a higher
risk of relapse. This included adalimumab vs infliximab
(HR, 1.21; 95% CI, 0.99–1.49) and second-line anti-TNF
therapy (HR, 1.32; 95% CI, 1.01–1.72). CD-specific risk
factors associated with relapse were younger age at CD
diagnosis (A1 vs A2 [16 years vs 17 - 40 years]) (HR,
Table 2. Baseline Patient Characteristics
N ¼ 1317 Missing, n (%)
Male, n (%) 567/1269 (44.7) 48 (3.6)
Median age, y (Q1–Q3) 35.0 (27.7–45.0) 132 (10)
Smoking, n (%) 354/1234 (28.7) 83 (6.3)
Median disease duration, y (Q1–Q3) 7.7 (3.7–13.0) 210 (15.9)
Disease location, n (%)
L1 ileal 296/1312 (22.6) 5 (0.38)
L2 colonic 341/1312 (26.0) 5 (0.38)
L3 ileocolonic 667/1312 (50.8) 5 (0.38)
L4 isolated 8/1312 (0.6) 5 (0.38)
þL4 upper GI disease 75/1255 (6.0) 62 (4.7)
Disease behavior, n (%)
B1 765/1230 (62.2) 87 (6.6)
B2 213/1230 (17.3) 87 (6.6)
B3 252/1230 (20.5) 87 (6.6)
Perianal disease, n (%) 352/1265 (27.8) 52 (3.9)
Previous intestinal resection, n (%) 320/1254 (25.5) 63 (4.8)
Second-line anti-TNF therapy, n (%) 120/830 (14.5)
Anti-TNF type, n (%)
Infliximab 927/1317 (70.4) 0 (0)
Adalimumab 390/1317 (29.6) 0 (0)
Median duration of anti-TNF therapy, mo (Q1–Q3) 23.0 (14.0–40.0) 223 (16.9)
Median remission length, mo (Q1–Q3) 20.3 (12.8–30.5) 1223 (93)
Anti-TNF trough level, therapeutic,a n (%) 138/255 (54.1) 1062 (80.6)
Anti-TNF intensifiedb 50/1034 (4.8) 283 (21.5)
Median infliximab trough level, mg/mL (Q1–Q3) 3.0 (1.1–6.9) 1148 (87.2)
Median adalimumab trough level, mg/mL (Q1–Q3) 4.7 (0.0–8.8) 1278 (97)
Anti-TNF antibodies, n (%) 21/154 (13.6) 1163 (88.3)
Immunosuppressant at baseline, n (%) 933/1285 (72.6) 32 (2.4)
Azathioprine 761/883 (86.2) 434 (33)
6-Mercaptopurine 47/883 (5.3) 434 (33)
6-Thioguanine 3/883 (0.3) 434 (33)
Methotrexate 70/883 (7.9) 434 (33)
Azathioprine and methotrexate 2/883 (0.2) 434 (33)
Clinical remission,c n (%) 1221/1246 (98) 71 (5.4)
Median hemoglobin level, mmol/L (Q1–Q3) 8.5 (7.9–9.1) 738 (56)
Median leukocyte count, 109/L (Q1–Q3) 6.5 (5.2–8.0) 497 (37.7)
Median thrombocytes, 109/L (Q1–Q3) 256.0 (217.5–307.0) 495 (37.6)
Median albumin level, g/L (Q1–Q3) 43.0 (39.5–46.0) 1008 (76.5)
Median CRP level, mg/L (Q1–Q3) 2.0 (0.7–4.0) 665 (50.5)
Median FC level, mg/g (Q1–Q3) 56.0 (30.0–168.0) 1020 (77.4)
Endoscopic remission,d n (%) 581/671 (86.6) 646 (49.1)
B, behavior; CRP, C-reactive protein; FC, fecal calprotectin; GI, gastrointestinal; L, location; Q, quartile; TNF, tumor necrosis factor.
aIFX 3 mg/mL, adalimumab 2.83 mg/mL.
bAnti-TNF high/intensified dose or interval (IFX >5 mg/kg or adalimumab >40 mg; IFX interval <1/8 wk or adalimumab interval <1/2 wk).
cDefined as (steroid-free) Crohn’s Disease Activity Index less than 150, Harvey Bradshaw Index less than 5, Physicians’ Global Assessment of 0.
dDefined as a simple endoscopic score for CD of 0 to 2, Crohn’s disease index of severity less than 3, Rutgeerts’ score of 0 to 1, no ulcerations/mucosal healing.
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Figure 1. Performance of the discontinuation in Crohn’s disease patients in stable Remission on combined therapy with
Immunosuppressants (STORI) trial, validated on (A) the total individual participant data meta-analysis cohort (n ¼ 1317), (B)
patients who fulfilled the inclusion criteria of the STORI trial (n ¼ 143), and (C) stratified per cohort.
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1.07; 95% CI, 0.98–1.17 per 5 years), and involvement of
the upper gastrointestinal tract (L4) (HR, 1.33; 95% CI,
0.97–1.82). Finally, smoking and younger age at anti-TNF
cessation were identified as risk factors (HR, 1.39; 95%
CI, 1.15–1.67; and HR, 1.16; 95% CI, 1.00–1.33 per
decade).
Biochemical Model
In addition to the identified clinical factors associated
with relapse, increased CRP was the only biochemical
marker associated with an increased risk of relapse (HR,
1.04; 95% CI, 1.00–1.08 per doubling) (Table 3). Adding
CRP to the clinical prediction model showed no increase in
performance (C-statistic, 0.59; 95% CI, 0.56–0.62)
(Figure 2A).
Endoscopic Model
Active inflammation at endoscopy was not associated
significantly with relapse (HR, 1.14; 95% CI, 0.80–1.64)independent of the clinical and biochemical risk factors.
Adding endoscopic findings to the prediction model
showed no increase in discriminative ability of the model
(C-statistic, 0.58; 95% CI, 0.55–0.61) (Table 3).
Individual Participant Data Meta-Analysis
Prediction Models on Studies Including Fecal
Calprotectin Levels
FC was associated with an increased risk of relapse in
all 3 models (Table 3). Adding FC led to higher
discriminative abilities in each of the 3 versions of the
prediction models (Figure 2B).
Decision Curve Analysis and Support Tool
The decision curve analysis showed that using the
biochemical model provided a net benefit in the
threshold probability range of relapse between 25% and
50% compared with default strategies (Supplementary
Figure 5). The biochemical model was transformed into
a clinical decision support tool, in which points were
Table 3. Constructed Prediction Models
Predictor





















Age, every 10 y 0.86 (0.75–1.00) 0.86 (0.75–1.00) 0.87 (0.75–1.00) 0.90 (0.71–1.14) 0.90 (0.71–1.14) 0.90 (0.71–1.14)
Smoking, yes 1.39 (1.15–1.67) 1.39 (1.15–1.67) 1.37 (1.15–1.64) 1.52 (1.10–2.08) 1.52 (1.10–2.08) 1.52 (1.10–2.08)
Age at diagnosis 17–40 y, A2 vs A1 0.68 (0.52–0.89) 0.69 (0.53–0.90) 0.69 (0.53–0.90) 0.46 (0.30–0.72) 0.46 (0.30–0.72) 0.46 (0.30–0.72)
Age at diagnosis >40 y, A3 vs A1 0.71 (0.40–1.25) 0.71 (0.40–1.25) 0.70 (0.40–1.25) 0.75 (0.29–1.91) 0.74 (0.29–1.92) 0.75 (0.29–1.98)
Any disease location, including L4 1.33 (0.97–1.82) 1.32 (0.96–1.79) 1.30 (0.95–1.79) 1.64 (0.98–2.78) 1.64 (0.98–2.70) 1.61 (0.98–2.63)
Disease duration, every 5 years 1.07 (0.98–1.17) 1.07 (0.98–1.17) 1.07 (0.98–1.17) 1.02 (0.90–1.16) 1.02 (0.90–1.16) 1.02 (0.90–1.16)
Immunosuppressant, yes 0.70 (0.58–0.85) 0.70 (0.58–0.85) 0.71 (0.58–0.86) 0.86 (0.61–1.22) 0.87 (0.61–1.23) 0.87 (0.62–1.23)
Adalimumab, vs IFX 1.21 (0.99–1.49) 1.22 (0.99–1.50) 1.22 (0.99–1.50) 1.04 (0.71–1.52) 1.04 (0.71–1.52) 1.02 (0.69–1.51)
Second-line anti-TNFa 1.32 (1.01–1.72) 1.32 (1.01–1.69) 1.30 (1.01–1.69) 1.72 (1.09–2.78) 1.72 (1.09–2.70) 1.72 (1.08–2.78)
Clinical remission,b yes 0.45 (0.24–0.84) 0.45 (0.25–0.83) 0.46 (0.25–0.83) 0.31 (0.16–0.58) 0.31 (0.16–0.58) 0.30 (0.16–0.57)
C-reactive protein, per doubling, mg/L 1.04 (1.00–1.08) 1.04 (1.00–1.08) 1.00 (0.94–1.08) 1.01 (0.94–1.08)
Fecal calprotectin, per doubling, mg/g 1.13 (1.02–1.27) 1.13 (1.02–1.27) 1.13 (1.01–1.27)
Endoscopic remission,c yes 0.88 (0.61–1.25) 0.86 (0.49–1.51)
A, age; C-statistic, concordance statistic; FC, fecal calprotectin; HR, hazard ratio; IFX, infliximab; IPD, individual participant data; L, location; TNF, tumor necrosis factor.
aOne or more anti-TNF therapies in the patient’s medical history.
bDefined as (steroid-free) Crohn’s Disease Activity Index less than 150, Harvey Bradshaw Index less than 5, Physicians’ Global Assessment of 0.













Figure 2. Internal–external validation of the (A) constructed biochemical model and the (B) biochemical model constructed on
the cohorts with available and added FC with corresponding calibration-in-the-large, calibration slope, and predictive per-
formance (C-statistic). Calibration-in-the-large measures whether predictions of the prediction model are on average too high
or too low and should ideally be equal to zero. Values less than zero indicate overestimation of the probability of relapse and
values greater than zero indicate underestimation of the probability of relapse. The calibration slope measures whether the
average predictor effect is correct and ideally should be equal to 1. Values less than 1 indicate too extreme predictor effects,
while values greater than 1 indicate too weak predictor effects. Small cohorts (<50 patients) were combined in the category of
“other.”
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(Table 4). Patients with a low risk of relapse could be
defined by the presence of 3 or fewer of the depicted
points, with a 22% risk of relapse over 1 year (sensi-
tivity, 79%; specificity, 39%). If high risk of relapse
would be defined by the presence of 5 or more points,
the risk of relapse would be more than 42% within 1
year (sensitivity, 37%; specificity, 78%) (Supplementary
Tables 6 and 7).Discussion
Personalized prediction of the risk of relapse after
anti-TNF cessation in CD is an important unmet need.
According to this IPD-MA of 1317 CD patients in remis-
sion, the overall risk of relapse after anti-TNF therapy
cessation is 38% at 1 year and 52% at 2 years. By
pooling all available data, a predictive diagnostic tool
with an overall moderate discriminative ability to prog-
nosticate relapse risk could be developed. The proposed
score chart for prediction of the risk of relapse in an
individual patient may serve as a shared decision-making
tool for clinical practice. This chart has a modest diag-
nostic accuracy both in identifying patients at risk ofrelapse below 22% within a year (3 points on the
diagnostic tool) (sensitivity, 79%; specificity, 39%), as
well as in identifying patients at risk of relapse exceeding
42% within a year (sensitivity, 37%; specificity, 78%).
According to the included IPD-MA study population,
approximately one third of patients will be in each risk
group. Therefore, an important implication of the model
is that it may not only support the decision of anti-TNF
cessation, but also will avoid detrimental anti-TNF
cessation in a considerable subgroup of patients with
significant risk of relapse.
The identified clinical risk factors in this IPD-MA are
in line with previous studies. Although previous cohort
studies have suggested a difference between ileal and
colonic disease as a prognostic factor, this IPD-MA only
confirmed upper gastrointestinal tract involvement as a
consistent risk factor for relapse.43 It may well be that
previous series were too small for accurate multivariable
analysis, and were not able to account for the correlation
of disease location with other risk factors. Because the
variance inflation factor for the clinical predictors was
low, it was shown that the model was not influenced by
collinearity, which also was true for factors that seem
correlated such as age at diagnosis and age at anti-TNF
cessation. In patients with a history of therapy-
Table 4. Score Chart for Prediction of the Individual Risk of









Age at diagnosis 16 y (A1) 2
No immunosuppressant 2
Steroid use 6–12 mo before cessation 2












A, age; L, location; CRP, C-reactive protein; TNF, tumor necrosis factor.
aDefined as Crohn’s Disease Activity Index of 150 or more, Harvey Bradshaw
Index of 5 or more, Physicians’ Global Assessment greater than 0.
- 2021 Predicting Safe Anti-TNF Cessation 13refractory CD or combination therapy at the time of
cessation, IS continuation at the moment of anti-TNF
cessation may be considered because the use of IS pro-
tects against relapse. In the developed model, clinical
remission was included as a predictor, which may be
regarded as a condition for cessation of anti-TNF. By
inclusion of these data, the model also is applicable to
patients with bowel symptoms. To explore the effect of
inclusion of this predictor, an additional subanalysis with
construction of the prediction model was performed,
restricted to patients in clinical remission, which showed
no change in other identified predictors (Supplementary
Table 8). With regard to the identified biochemical
markers, a low CRP and FC level were associated with a
favorable outcome after anti-TNF cessation in this IPD-
MA, in accordance with available literature.12,32,36
Endoscopy to confirm disease remission before anti-
TNF cessation does not add to the risk estimation of
CD relapse. This finding possibly could be explained by
the selection of patients for anti-TNF cessation in avail-
able studies because 87% of patients with available
endoscopic data were in endoscopic remission, and 99%
of patients with endoscopic remission were also in clin-
ical and/or biochemical remission. We presume thatendoscopic remission is a predictor of relapse when
considering all CD patients, but not anymore in the
selected subgroup of patients for which one reasonably
would consider anti-TNF cessation in clinical practice. It
should be noted that the predictive value of histologic
remission as a possible protective factor for relapse was
not investigated in this IPD-MA; further studies are
required to investigate this possible predictor.11,44
Remarkably, the STORI prediction model12 could not
be validated in this IPD-MA. We observed that the
identified risk factors by this IPD-MA and in the STORI
trial showed similarity in direction, pointing at a pro-
tective or increased risk of relapse. Despite this simi-
larity, the predictive power of 0.51 was lower compared
with the predictive performance of 0.71 in the initial
publication, with overprediction of relapse risk in most
cohorts. The disappointing performance of the STORI
prediction model in this IPD-MA potentially may be
explained by statistical overfitting in a relatively small
population (115 patients, 52 relapses). In addition,
dichotomization of predictors and categorization of var-
iables in the analysis of the STORI trial may be seen as
introducing an extreme form of rounding, with an inev-
itable loss of information and power.45,46
Even though the study size in this IPD-MA was rather
large, it has resulted in a predictive diagnostic tool that
requires further refinement. To this end, more data on FC
and other biochemical, genetic, and/or histologic
markers are needed. Because of the high numbers of
missing values, serum albumin and anti-TNF serum
concentrations could not be analyzed as risk factors for
relapse. However, biomarkers closely related to the
pathophysiology of CD might be most promising. Several
potential DNA, messenger RNA, and protein markers
were evaluated previously to predict response to anti-
TNF treatment.47 Interesting genetic associations
include IBD5 and NOD2/CARD15 mutations, as well as
FCGR3A 158V/V genotype polymorphisms.31,48 In addi-
tion, mucosal cytokines need further exploration (eg, as
mucosal TNF and/or interleukin 17a expression).49 Mi-
crobial dysbiosis with decreased diversity warrants
further exploration.50
In addition to the risk of exacerbation after cessation
of anti-TNF, the efficacy of re-treatment of anti-TNF in
case of a relapse is an important clinical issue, even in
this era of expanding medical treatment options for CD. A
period without anti-TNF therapy, or so-called drug hol-
iday, has been associated with an increased risk of im-
munization potentially leading to a loss of treatment
effect after re-introduction.51 Pooled IPD-MA data anal-
ysis on the effect of re-treatment was not justified in the
current data set because of considerable missing values.
In Supplementary Table 9 an overview of the data on the
efficacy of re-treatment was depicted and showed that
response to reintroduction after relapse was consider-
ably high (ie, up to > 80% in large cohorts).39,40
Although this IPD-MA was performed following the
Transparent Reporting of a multivariable prediction
14 Pauwels et al Clinical Gastroenterology and Hepatology Vol. -, No. -model for Individual Prognosis Or Diagnosis statement, a
few limitations need to be addressed. First, 11 cohorts
published in the literature were excluded owing to un-
availability of IPD. In particular, the low number of
included Asian cohorts may limit the external validity of
this IPD-MA to Western countries. Second, the model
predicts the risk of relapse 1 year after cessation of anti-
TNF, and may not prognosticate the risk at long-term
follow-up evaluation. Third, the model is only appli-
cable to patients who started anti-TNF for the indication
of luminal CD (not perianal CD). Third, heterogeneity
may occur owing to the inclusion of different studies into
the model development. In this IPD-MA, we developed
the prediction model by adding a stratified baseline
hazard for each study to ensure that the effects of pre-
dictors are based on within-study effects and not an
artifact of between-study differences. In addition, inter-
action tests between predictors and retrospective or
prospective study design were nonsignificant. These
findings indicate that pooling of the data from these
different studies is reasonable. Fourth, in this IPD-MA the
developed model was validated by using an
internal–external validation procedure. Nevertheless,
further external validation is required. Finally, FC levels
were available only in relatively small study populations.
Therefore, the constructed prediction model including FC
has to be validated in an external, independent, real-
word patient cohort with available FC to enhance its
predictive performance.
In conclusion, a clinically relevant predictive diag-
nostic tool to cease anti-TNF in CD has been developed
based on multiple cohorts. The proposed simple score
chart might be used to guide clinical decision making
after further external validation. Future updating of the
prediction model with FC and other potent biomarkers is
desired to improve identification of CD patients at low
and high risk of relapse after anti-TNF cessation.
Furthermore, to determine the (cost-) effectiveness of
the model, long-term follow-up studies are required.
Eventually, anti-TNF cessation after individual risk esti-
mation will improve the quality of care to CD patients by
implementation of uniform treatment protocols.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2021.03.037.References
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diseas*) OR crohn* OR ibd):ab, ) AND ('drug withdrawal'/exp OR 'treatment withdrawal'/de OR 
(((drug* OR agent* OR medicat* OR tnf OR tumor-necrosis-factor OR therap* OR treat* OR 
infliximab* OR adalimumab* OR golimumab* OR mercaptopurin*) NEAR/6 (withdraw* OR cessat* 
OR abs nen* OR stop* OR discon nu*)) OR ((withdraw* OR stop) NEAR/3 (criteria* OR ming OR 
when))):ab, ) AND ('tumor necrosis factor inhibitor'/de OR 'tumor necrosis factor alpha inhibitor'/de 
OR 'tumor necrosis factor an body'/de OR 'tumor necrosis factor alpha an body'/de OR 'biological 
therapy'/de OR 'infliximab'/mj  OR adalimumab/mj OR golimumab/mj OR 'mercaptopurine'/mj OR 
(((tnf* OR necrosis-factor*) NEAR/6 (an * OR inhibitor* OR block* OR antagon* OR target* OR 
against*)) OR biological* OR infliximab* OR adalimumab* OR golimumab* OR mercaptopurin*):ab, ) 
AND [english]/lim
Medline Ovid
("Inflammatory Bowel Diseases"/ OR "Crohn Disease"/ OR ((inflammat* ADJ3  bowel ADJ3  diseas*) 
OR crohn* OR ibd).ab, .) AND ("Withholding Treatment"/ OR "Substance Withdrawal Syndrome"/ 
OR (((drug* OR agent* OR medicat* OR tnf OR tumor-necrosis-factor OR therap* OR treat* OR 
infliximab* OR adalimumab* OR golimumab*) ADJ6 (withdraw* OR cessat* OR abs nen* OR stop* 
OR discon nu*)) OR ((withdraw* OR stop) ADJ3 (criteria* OR ming OR when))).ab, .) AND ("tumor 
necrosis factor"/ai OR "Biological Therapy"/ OR *"infliximab"/  OR *adalimumab/ OR *golimumab/ 
OR (((tnf* OR necrosis-factor*) ADJ6 (an * OR inhibitor* OR block* OR antagon* OR target* OR 
against*)) OR biological* OR infliximab* OR adalimumab* OR golimumab*).ab, .) AND english.la.
Cochrane 
(((inflammat* NEAR/3 bowel NEAR/3 diseas*) OR crohn* OR ibd):ab, ) AND ((((drug* OR agent* OR 
medicat* OR tnf OR tumor-necrosis-factor OR therap* OR treat* OR infliximab* OR adalimumab* OR 
golimumab*) NEAR/6 (withdraw* OR cessat* OR abs nen* OR stop* OR discon nu*)) OR 
((withdraw* OR stop) NEAR/3 (criteria* OR ming OR when))):ab, ) AND ((((tnf* OR necrosis-factor*) 
NEAR/6 (an * OR inhibitor* OR block* OR antagon* OR target* OR against*)) OR biological* OR 
infliximab* OR adalimumab* OR golimumab*):ab, )
Web of science  
TS=((((inflammat* NEAR/2  bowel NEAR/2  diseas*) OR crohn* OR ibd)) AND ((((drug* OR agent* OR 
medicat* OR tnf OR tumor-necrosis-factor OR therap* OR treat* OR infliximab* OR adalimumab* OR 
Supplementary Figure 1. Systematic search.
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golimumab* OR methotrexat* OR "mtx") NEAR/5 (withdraw* OR cessat* OR abs nen* OR stop* OR 
discon nu*)) OR ((withdraw* OR stop) NEAR/2 (criteria* OR ming OR when)))) AND ((((tnf* OR 
necrosis-factor*) NEAR/5 (an * OR inhibitor* OR block* OR antagon* OR target* OR against*)) OR 
biological* OR infliximab* OR adalimumab* OR golimumab*))) AND LA=(english)
Google scholar 
"inflammatory bowel diseases"|crohn|ibd 
withdrawal|cessa on|discon nua on|discon nuing|"stopping criteria" "an  tnf"|"an  
tumor|tumour necrosis"|"tumor|tumour necrosis factor 
inhibitor|inhibitors|blocking|antagonist|antagonists"




951 Web of Science




4364 excluded on tle/abstract
106 duplicate/congress abstract
44 cohorts < 30 CD pa ents
65 (narra ve) reviews 
/editorials/protocols
3 no full-text / abstract available
2 an -TNF < 6M
1 age < 16 years
29 eligible studies
14 eligible studies with IPD
10 no IPD received 
5 iden cal cohorts 
Supplementary Figure 2. Flow chart of study selection. CD,
Crohn’s disease; IPD, individual patient data; M, months;
TNF, tumor necrosis factor.
Total IPD received, n=1777
<6M an -TNF therapy, n=181
An -TNF started for perianal disease, n=155
No follow-up, n=22
No steroid free remission, n=70
Ulcera ve coli s, n=18
Total included pa ents, n=1317
Age <16 years, n=13
Certolizumab, n=1
Supplementary Figure 3. Flowchart of individual participant
data selection. IPD, individual participant data; M, months;
TNF, tumor necrosis factor.
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Supplementary Figure 4. Incidence of relapse, categorized by study.
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Cease anti−TNF for none
Cease anti−TNF for all
Supplementary Figure 5. Decision curve analysis for the
prediction of relapse using the biochemical model. Solid
black line shows the assumption that patients continue
anti–tumor necrosis factor (TNF) therapy. Solid grey line
shows the assumption that all patients cease anti-TNF ther-
apy. Dotted line depicts the net benefit using the biochemical
model. The net benefit is the sum of benefit (ie, no relapse
after anti-TNF cessation) minus harms (ie, relapse after anti-
TNF cessation). Threshold probability is the accepted risk of
relapse after anti-TNF cessation. The net benefit of the
biochemical model is higher compared with anti-TNF
cessation in all patients as applied by the included studies
and with anti-TNF continuation in all patients, in the threshold
probability range of 0.25 to 0.5. Because risk thresholds are
subjective to patient and physician preferences, a range of
risk thresholds needs to be investigated. In this figure, the net
benefit was plotted for the total individual patient data meta-
analysis cohort against a range of clinically relevant risk
thresholds.
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Supplementary Table 1. Study Characteristics of Excluded Studies as a Result of Unavailability of IPD




participants, N Definition of remission Definition of relapse
Schnitzler et al16 Prospective Belgium 2008 110 Sustained clinical
remission; a lasting
control of disease




Armuzzi et al17 Abstract,
retrospective
Italy 2010 69 Prolonged steroid-free
remission
NR









anti-TNF agent or use
of systemic steroids









Dai et al20 Prospective,
observational




of >100 points in CDAI
and a CDAI of >150
points
Ampuero et al21 Retrospective Spain 2015 55 Steroid free clinical
remission; CDAI <150
CDAI >250




2016 42 Clinical remission; HBI <5 NR




with a biologic therapy
or systemic steroid or
CD-related surgery
Endoscopic relapse was
defined as SES-CD >2
Zheng et al24 Abstract,
retrospective





Retrospective Denmark 2018 33 Clinical and biochemical
remission; HBI <5 and
a FC level of <200 mg/g
Surgery, reinstitution of
anti-TNF therapy, or
start of steroids or other
biological agents
CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; FC, fecal calprotectin; FU, follow-up; HBI, Harvey Bradshaw Index; IPD, individual participant data;
MRI, magnetic resonance imaging; NR, not reported; SES, simple endoscopic score; TNF, tumor necrosis factor.
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Supplementary Table 2. Identical Study Cohorts
Study Year Identical cohort
Waugh et al26 2010 Identical cohort to Lu et al1
de Suray et al27 2012 Subanalysis of the STORI cohort3
Rajca et al28 2014 Subanalysis of the STORI cohort3
Ternant et al29 2015 Subanalysis of the STORI cohort3
Reenaers et al30 2018 Long-term follow-up evaluation of
the STORI cohort3
STORI, diSconTinuation in CrOhn’s disease patients in stable Remission on
combined therapy with Immunosuppressants.










Lu et al1 2010 *** * * *****
Molnar et al2 2012 *** * ** ******
Louis et al3 2012 *** ** *** ********
Steenholdt et al4 2012 *** * ** ******
Chauvin et al5 2014 *** * ** ******
Farkas et al6 2014 *** * ** ******
Brooks et al7 2015 *** * *** *******
Bortlik et al8 2015 *** * ** ******
Ben-Horin et al9 2015 *** * *** *******
Kennedy et al10 2016 *** * *** *******
Casanova et al11 2017 *** * ** ******
García Ortíz et al12 2017 *** * * *****
Lin et al13 2017 *** * ** ******
Bots et al14 2019 *** * ** ******
The Newcastle–Ottawa Scale scores the quality of the design of (cohort) studies. The Newcastle–Ottawa Quality Assessment Form for Cohort Studies system has
been developed with stars, in which studies were scored on the following: (1) selection of study groups, (2) comparability of groups, and (3) the outcome of interest.
The total score can range from 0 (low) to 9 (high) stars.
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Supplementary Table 4. Risk of Bias Assessment After PROBAST
Study
ROB Applicability Overall
Participants Predictors Outcome Analysis Participants Predictors Outcome ROB Applicability
Lu et al1 þ ? þ - þ ? þ - ?
Molnar et al2 þ þ þ ? þ þ þ ? þ
Louis et al3 þ þ þ þ þ þ þ þ þ
Steenholdt et al4 þ ? þ ? - þ þ ? -
Chauvin et al5 þ ? þ ? þ þ þ ? þ
Farkas et al6 þ þ þ - - þ þ - -
Brooks et al7 þ þ þ þ þ þ þ þ þ
Bortlik et al15 þ ? þ ? þ þ þ ? þ
Ben-Horin et al9 þ þ þ ? - þ þ ? -
Kennedy et al10 þ þ þ þ þ þ þ þ þ
Casanova et al11 þ þ þ ? þ þ þ ? þ
García Ortíz et al12 þ ? - - þ þ þ - þ
Lin et al13 þ ? þ ? þ þ þ ? þ
Bots et al14 þ ? þ þ þ þ þ ? þ
PROBAST, prediction model risk of bias assessment tool; ROB, risk of bias; þ, indicates low ROB/low concern regarding applicability; -, indicates high ROB/high
concern regarding applicability; ?, indicates unclear ROB/unclear concern regarding applicability.
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Supplementary Table 5. Univariable Analysis of
Associations Between Clinical,
Biochemical, and Endoscopic
Parameters and Relapse After Anti-
TNF Cessation
Predictor HR (95% CI)
Clinical symptoms 3.85 (2.38–6.25)
Smoking, yes 1.28 (1.08–1.52)
Immunosuppressant, yes 0.75 (0.63–0.89)
Any disease location including L4 vs no L4 1.22 (0.91–1.67)
Second-line anti-TNF 1.33 (1.05–1.69)
Adalimumab vs infliximab 1.21 (1.02–1.44)
Disease duration, every 5 y 1.02 (0.97–1.08)
Age, every 10 y 0.87 (0.81–0.92)
Female sex 1.09 (0.93–1.28)
Age at diagnosis 17–40 y, A2 vs A1 0.61 (0.49–0.75)
Age at diagnosis >40 y, A3 vs A1 0.45 (0.32–0.63)
Colon localization, L2 vs L1 1.18 (0.93–1.49)
Ileocolic localization, L3 vs L1 1.33 (1.08–1.62)
Isolated upper GI involvement 1.97 (0.81–4.81)
Stricturing disease, B2 vs B1 1.03 (0.83–1.28)
Penetrating disease, B3 vs B1 0.95 (0.76–1.18)
Perianal (fistulizing) disease, yes 0.95 (0.79–1.14)
Previous intestinal resection, yes 1.09 (0.93–1.30)
Duration of anti-TNF therapy, every 12 mo 1.00 (0.95–1.04)
Escalated anti-TNF therapy,a yes 1.17 (0.80–1.72)
Previous IS use, yes 0.88 (0.60–1.28)
Two previous IS vs 1 1.12 (0.85–1.46)
Three previous IS vs 1 1.02 (0.60–1.73)
Type of previous IS, thiopurine, vs no 0.84 (0.61–1.16)
Type of previous IS, MTX, vs no 1.56 (0.94–2.58)
Type of previous IS, MTX, vs thiopurine 1.46 (0.96–2.21)
Type of previous IS, thiopurine and MTX,
vs thiopurine
1.10 (0.83–1.46)
Platelet count,b per 100 *109 increase 1.07 (0.94–1.21)
Hemoglobin level, per 1-mmol/L increase 1.00 (0.89–1.13)
Leukocyte count, per 1-109/L increase 1.03 (0.99–1.08)
CRP, per doubling, mg/L 1.02 (0.97–1.06)
FC, per doubling, mg/g 1.03 (0.97–1.10)
Endoscopic remission, yes 0.85 (0.65–1.12)
A, age; B, behavior; CRP, C-reactive protein; FC, fecal calprotectin; GI,
gastrointestinal; HR, hazard ratio; IS, immunosuppressant; L, location; MTX,
methotrexate; TNF, tumor necrosis factor.
aInfliximab greater than 5 mg/kg or adalimumab greater than 40 mg, or inflix-
imab interval <1/8 wk or adalimumab interval <1/2 wk.
bNo further increase in risk was observed for platelet count of 300*109 or
greater.
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Supplementary Table 6. Relapse Rates Based on the Allocated Points From the Simple Score Chart to Each Patient
(According to the Biochemical Model)
Allocated points
from the score










1a 99 3 1292 (98) 25 (2) 33 13
2 95 11 1205 (91) 112 (9) 34 21
3 79 39 903 (69) 414 (31) 37 22
4 60 59 645 (49) 672 (51) 40 26
5 37 78 372 (28) 945 (72) 42 29
6 20 89 200 (15) 1117 (85) 43 31
7 11 96 100 (8) 1217 (92) 45 32
8 4 99 36 (3) 1281 (97) 53 32
aNo patients with less than 1 point were identified in the individual participant data meta-analysis cohort.
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Supplementary Table 7. Sensitivity and Specificity Values of
Different Relapse Rate Thresholds
According to the Biochemical
Model
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Supplementary Table 8. Constructed Prediction Models Restricted to Patients in Clinical Remission (n ¼ 1221)
Predictor





















Age, every 10 y 0.84 (0.73–0.98) 0.85 (0.73–0.98) 0.85 (0.73–0.98) 0.86 (0.67–1.09) 0.85 (0.66–1.09) 0.84 (0.65–1.09)
Smoking, yes 1.42 (1.18–1.73) 1.42 (1.18–1.72) 1.41 (1.17–1.72) 1.52 (1.09–2.10) 1.53 (1.04–2.24) 1.52 (1.04–2.25)
Age at diagnosis 17–40 y, A2 vs A1 0.71 (0.53–0.95) 0.70 (0.52–0.94) 0.70 (0.52–0.94) 0.49 (0.31–0.76) 0.48 (0.30–0.77) 0.48 (0.31–0.77)
Age at diagnosis >40 year, A3 vs A1 0.76 (0.41–1.44) 0.74 (0.39–1.40) 0.74 (0.39–1.41) 0.70 (0.25–1.96) 0.69 (0.23–2.02) 0.70 (0.24–2.08)
Any disease location, including L4 1.32 (0.96–1.81) 1.31 (0.96–1.79) 1.29 (0.95–1.77) 1.75 (1.04–2.95) 1.58 (0.92–2.71) 1.55 (0.9–2.68)
Disease duration, every 5 years 1.07 (0.97–1.17) 1.06 (0.97–1.17) 1.06 (0.97–1.17) 1.03 (0.89–1.19) 1.03 (0.89–1.21) 1.03 (0.89–1.20)
Immunosuppressant, yes 0.70 (0.57–0.85) 0.70 (0.57–0.86) 0.71 (0.57–0.87) 0.83 (0.58–1.20) 0.88 (0.60–1.27) 0.88 (0.61–1.26)
Adalimumab, vs IFX 1.24 (0.99–1.55) 1.25 (1.00–1.55) 1.25 (0.99–1.57) 0.95 (0.66–1.37) 0.97 (0.63–1.50) 0.96 (0.62–1.50)
Second-line anti-TNFa 1.26 (0.88–1.80) 1.24 (0.87–1.77) 1.22 (0.82–1.83) 2.1 (1.31–3.36) 1.72 (1.09–2.70) 2.19 (1.18–4.07)
C-reactive protein, per doubling, mg/L 1.06 (0.97–1.16) 1.06 (0.97–1.16) 1.00 (0.93–1.08) 1.00 (0.93–1.08)
Endoscopic remission,b yes 0.90 (0.60–1.35) 0.88 (0.51–1.51)
FC, per doubling, mg/g 1.14 (1.03–1.25) 1.12 (1.0–1.26) 1.12 (1.0–1.25)
A, age; C-statistic, concordance statistic; FC, fecal calprotectin; HR, hazard ratio; IFX, infliximab; L, location; TNF, tumor necrosis factor.
aOne or more anti-TNF therapies in the patient’s medical history.

































n (%) Surgery, n (%) Efficacy Side effects
Lu et al1 2010 NR NR NR NR NR NR NR NR NR NR
Louis et al3 2012 CDAI decrease

















































Infection, n ¼ 2
Cancer, n ¼ 1
Other, n ¼ 2









7/47 (15%) NR 1/7 (14%) (40
missing values)















































































































































n (%) Surgery, n (%) Efficacy Side effects




















NR NR NR NR
Bortlik et al8 2015 Efficacy was
assessed
NR NR NR NR NR NR NR NR NR
Ben-Horin
et al9





































































































n (%) Surgery, n (%) Efficacy Side effects
Casanova
et al11




























































Lin et al13 2017 Clinical
response and
remission









































n ¼ 1 (35
missing
values)
CDAI, Crohn’s Disease Activity Index; HBI, Harvey Bradshaw Index; IS, immunosuppressant; NR, not received; PGA, physician’s global assessment; TNF, tumor necrosis factor.
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